Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Rheumatology

FDA Approves 3D Printed Implant for Avascular Necrosis of the Talus

Brian Park, PharmD

February 24, 2021

The FDA has approved the Patient Specific Talus Spacer for humanitarian use in the treatment of avascular necrosis of the ankle joint.

General Rheumatology

FDA Approves Emergency Use of Bamlanivimab Plus Etesevimab for COVID-19

Brian Park, PharmD

February 22, 2021

The FDA has issued an Emergency Use Authorization for Lilly’s SARS-CoV-2 neutralizing antibodies bamlanivimab plus etesevimab.

Systemic Lupus Erythematosus

Voclosporin Approved for Active Lupus Nephritis

Brian Park, PharmD

February 11, 2021

The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.

General Rheumatology

J&J Single-Dose COVID-19 Vaccine 66% Effective at Preventing Moderate/Severe Disease

Brian Park, PharmD

February 4, 2021

Single-dose vaccine candidate JNJ-78436725 against COVID-19 met primary and key secondary end points.

Scleroderma

Sitaxsentan Designated Orphan Drug for Systemic Sclerosis

Brian Park, PharmD

February 2, 2021

The FDA has granted Orphan Drug designation to TMB-003 (Timber Pharmaceuticals) for the treatment of systemic sclerosis.

Rheumatoid Arthritis

Tofacitinib vs TNFi for RA: Safety Study Results Announced

Brian Park, PharmD

February 1, 2021

The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.

General Rheumatology

FDA: False Results Possible With Curative SARS-Cov-2 Test

Brian Park, PharmD

January 15, 2021

The FDA is alerting patients and health care providers regarding the risk of false negatives for COVID-19 when using the Curative SARS-Cov-2 test.

General Rheumatology

Anakinra Approved for Deficiency of IL-1 Receptor Antagonist

Brian Park, PharmD

January 7, 2021

Kineret blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the IL-1 type I receptor.

General Rheumatology

Phase 3 Trial of Novavax’s COVID-19 Vaccine Begins

Brian Park, PharmD

January 6, 2021

The vaccine candidate contains the Company’s saponin-based Matrix-M™ adjuvant technology to enhance and prolong immune responses.

General Rheumatology

Ruxolitinib Not Beneficial for COVID-19-Associated Cytokine Storm

Brian Park, PharmD

December 22, 2020

A phase 3 study evaluating the efficacy and safety of ruxolitinib for the treatment of COVID-19 did not meet its primary end point.

Next post in General Rheumatology